Inicio › Enfermedad de obstrucción pulmonar crónica › Indiana
Ensayos clínicos de Enfermedad de obstrucción pulmonar crónica en Indiana
11 estudios sobre Enfermedad de obstrucción pulmonar crónica buscan participantes en Indiana.
Ciudades en Indiana
Texto oficial del estudio (inglés)
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
- Velocity Clinical Research ( Site 4464), Valparaiso
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 6 nov 2026 · NCT07874815A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Indiana University Health University Hospital, Indianapolis
- IU Health Ball Memorial Hospital, Inc., Muncie
ReclutandoFase 2
Edades de 40 a 75 · Todos los sexos · Actualizado el 5 nov 2026 · NCT07759245To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- DM Clinical Research-Indianapolis, Indianapolis
ReclutandoFase 2
Edades de 40 a 85 · Todos los sexos · Actualizado el 28 oct 2026 · NCT07684820Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Asha Clinical Research - Munster- Site Number : 8400115, Hammond
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 23 oct 2026 · NCT07190222A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- ASHA Clinical Research - Munster, LLC, Hammond
- Methodist Hospital Southlake, Merrillville
ReclutandoFase 2/3
Edades de 35 a 80 · Todos los sexos · Actualizado el 22 oct 2026 · NCT07363694Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Indy Clinical Research- Site Number : 8400071, Indianapolis
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 19 oct 2026 · NCT07190209The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
- IU Health Pulmonology & Critical Care Medicine, Indianapolis
ReclutandoEstudio observacional
Edades de 40 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07612878A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Evansville
- Research Site, Indianapolis
- Research Site, Indianapolis
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 9 oct 2026 · NCT06878261Acoustic Waveform Respiratory Evaluation
- Indiana University, Indianapolis
ReclutandoSe aceptan voluntarios sanos
Edades de 8 a 70 · Todos los sexos · Actualizado el 5 oct 2026 · NCT06512064A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Valparaiso
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 2 oct 2026 · NCT06283966A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Munster
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06883305De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.